Kawasaki Goro, Yoshitomi Izumi, Yanamoto Souichi, Yamada Shinichi, Mizuno Akio
Dept. of Oral and Maxillofacial Surgery, Unit of Translational Medicine, Course of Medical and Dental Sciences, Nagasaki University Graduate School of Biomedical Sciences.
Gan To Kagaku Ryoho. 2011 Jun;38(6):951-7.
S-1 is a newly developed oral fluoropyrimidine derivative that is now widely used as a chemotherapeutic agent in the treatment of various carcinomas. This study was performed to assess the efficacy and safety profile of the combination of S-1 and cisplatin(S-1/CDDP)in patients with oral cancer as neo-adjuvant chemotherapy. We reviewed our experience of 12 patients diagnosed with oral carcinoma, who were treated with S-1/CDDP. S-1 was administered orally at a dose of 50mg twice a day for 21 consecutive days, followed by a 14-day rest period. CDDP(60mg/m2)in 500 mL physiological saline was administered by intravenous drip as a 120-min infusion on day 8, together with standard premedications and hydration. Seven partial responders were obtained. The median follow-up duration was 54. 8 months, and all patients were alive excluding one case. This regimen was well tolerated, with only one case of grade 3 thrombocytopenia, and no grade 4 patient. No treatment-related death was observed. Moreover, we evaluated immunohistochemical expressions of thymidylate synthase (TS), dihydropyrimidine dehydrogenase(DPD), and orotate phosphoribosyl transferase(OPRT)which are associated with chemosensitivity to 5-FU-based therapies. We investigated the relation between the immunohistochemical score and clinicopathological factors, however we could not clarify the relationship between the efficacy of chemotherapy and results of immunohistochemistry.
S-1是一种新开发的口服氟嘧啶衍生物，目前作为化疗药物广泛用于治疗各种癌症。本研究旨在评估S-1和顺铂联合用药（S-1/CDDP）作为新辅助化疗治疗口腔癌患者的疗效和安全性。我们回顾了12例经S-1/CDDP治疗的口腔癌患者的经验。S-1口服给药，剂量为50mg，每日2次，连续21天，随后休息14天。第8天，将500mL生理盐水中的顺铂（60mg/m²）静脉滴注120分钟，并给予标准的预处理药物和补液。获得了7例部分缓解者。中位随访时间为54.8个月，除1例患者外，所有患者均存活。该方案耐受性良好，仅1例3级血小板减少，无4级患者。未观察到与治疗相关的死亡。此外，我们评估了胸苷酸合成酶（TS）、二氢嘧啶脱氢酶（DPD）和乳清酸磷酸核糖基转移酶（OPRT）的免疫组化表达，这些与基于5-氟尿嘧啶治疗的化疗敏感性相关。我们研究了免疫组化评分与临床病理因素之间的关系，但未能阐明化疗疗效与免疫组化结果之间的关系。
